Search
TAK-611
go.drugbank.com/drugs/DB17644InvestigationalFirst developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.
Escin
go.drugbank.com/drugs/DB15907InvestigationalSodium aescinate is under investigation in clinical trials for its potential to treat cerebral conditions, including NCT04247659 (studying the relationship between asymmetric vascular sign of cortex and
humanized SMART Anti-IL-12 Antibody
go.drugbank.com/drugs/DB05848ExperimentalThe humanized anti-IL-12 antibody is an important addition to PDL's already strong pipeline of humanized antibodies being developed for the treatment of autoimmune diseases. … SMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La Roche Inc
XL999
go.drugbank.com/drugs/DB05014InvestigationalXL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. … XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response.
Cannabinor
go.drugbank.com/drugs/DB05048ExperimentalCannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Sovateltide
go.drugbank.com/drugs/DB06138InvestigationalIn animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.
Rabeximod
go.drugbank.com/drugs/DB05772InvestigationalRabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Felcisetrag
go.drugbank.com/drugs/DB12725InvestigationalFelcisetrag (TD-8954) has been used in trials studying the treatment of Enteral Feeding Intolerance and Gastrointestinal Motility Disorder.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeVTP-201227
go.drugbank.com/drugs/DB05652ExperimentalIt is being developed by Vitae Pharmaceuticals. … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.